Hey GPT, Fact Check this post: GPT: "I verified the claims using **public information available as of 15 March 2026**. Below is a strict fact check of the specific assertions in the post.
---
# 1. Does NWBO have a London instrument **0K95**?
Yes.
There is a London market reference page for **Northwest Biotherapeutics** under ticker **0K95** with ISIN **US66737P6007**. ([London Stock Exchange][1])
However, key details:
* It appears in **LSEG reference / market-data systems**. * Trading activity is extremely limited or absent. * Some data pages show **zero recent trades**. ([ADVFN UK][2])
**Conclusion:** 0K95 exists as a **reference instrument**, but that alone does **not prove active LSE trading or settlement events**.
---
# 2. Is NWBO trading around **$0.22–$0.23** OTC right now?
Yes.
Recent data shows:
* NWBO price around **$0.23** * 52-week range roughly **$0.17–$0.48**. ([Robinhood][3])
So the post’s claim about a **~$0.22 OTC price** is consistent with current market data.
---
# 3. Did “sovereigns buy 165,000,000 shares at $1.71”?
No evidence.
The post claims:
* 165M shares bought * $282M moved to the company treasury * at a “London floor price”
There is **no SEC filing, company announcement, or exchange notice** supporting that transaction.
* it would require an **SEC 8-K or similar disclosure** * none is visible in current public data.
**Conclusion:** This claim is unsupported.
---
# 4. Is there a **$1.71 LSE settlement floor**?
No.
There is **no exchange rule, clearing rule, or regulatory framework** stating that:
* NWBO settles at a fixed **£1.26 / $1.71 London price** * OTC trades must bridge to that price.
Equities settle based on **actual executed trade prices**, not a “hard-coded exchange anchor”.
---
# 5. Does MiFID / TRADEcho create forced buy-ins like the post claims?
No.
MiFID / MiFIR frameworks are primarily about:
* transparency * reporting * trade publication
They **do not create automatic cross-market arbitrage penalties** like the post describes. ([AFME][5])
Settlement discipline in Europe comes from **CSDR**, but:
* mandatory buy-ins have been **delayed and revised repeatedly** * there is no mechanism matching the described **$1.42 per share penalty extraction**.
---
# 6. Is there a “sovereign vault draining market maker collateral”?
No credible source supports this concept.
There is **no recognized clearinghouse mechanism** called:
# 8. Delaware court “deleting 17% of 2020 options”
There **is** a real Delaware litigation settlement involving NWBO options.
But:
* it concerns **corporate governance litigation** * not market structure * not short selling * not share locates.
The post mixes that real event into an unrelated narrative.
---
# 9. The math in the post
The math itself is simply:
165M × $1.71 = $282.15M $1.71 - $0.29 = $1.42
But those calculations are meaningless unless the **premises are real**, which they are not.
---
# Final assessment
| Claim | Reality | | -------------------------------------- | -------------------- | | 0K95 instrument exists | True | | NWBO trades ~ $0.22 OTC | True | | 165M shares bought at $1.71 | No evidence | | $282M treasury funding | No evidence | | $1.71 LSE settlement floor | False | | $1.42 arbitrage penalty | Unsupported | | Sovereign vault draining market makers | Not a real mechanism | | MM insolvency | No evidence |
**Overall:** The post combines **real identifiers and numbers with speculative or invented market mechanics**. There is **no verifiable evidence (as of 15 March 2026)** that NWBO shares are being settled through a hidden London mechanism extracting hundreds of millions from market makers.
---
If you want, I can also show you something interesting about **0K95 specifically** that explains why it keeps appearing in NWBO discussions.
It has to do with **how global securities reference data propagates across exchanges**, and many investors misinterpret that as hidden trading.
Market Data 
Markets 
AI
